Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
$2.86-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-71.3%
The outlook
Elicio Therapeutics, Inc. currently reads as leaning bearish based on below its 50- & 200-day averages, 1% of the way from its 52-week low to high, avg target +599% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +599% vs current price
Analyst price target
~12-month · 3 analysts$20.00average target+599.3% vs now
Now $2.86
Low $10.00High $27.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$75.1M
52-wk high
$16.00
52-wk low
$2.66
50-day avg
$6.54
200-day avg
$8.87
Trailing P/E
—